Lux Med Diagnostyka
- Address
- Wichrowa 1A, 60-101 Poznan, Poland
Lux Med Diagnostyka - Advanced Lung Cancer Research
Lux Med Diagnostyka is a medical research facility dedicated to advancing the treatment of complex oncological conditions. The center specializes in conducting clinical trials for patients with advanced malignancies, with particular emphasis on developing novel therapeutic approaches for advanced and metastatic non-small cell lung cancer (NSCLC).
- Comparative efficacy studies of innovative antibody-drug conjugates versus standard chemotherapy
- Treatment strategies for NSCLC patients with and without actionable genomic alterations
- Evaluation of progression-free survival (PFS) and overall survival (OS) endpoints in advanced lung cancer
The center's research portfolio focuses on previously treated patients with metastatic lung cancer, contributing to the development of next-generation targeted therapies. Through rigorous clinical investigation, Lux Med Diagnostyka plays a vital role in evaluating therapeutic alternatives for patients who have exhausted standard treatment options, particularly in the rapidly evolving field of precision oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lux Med Diagnostyka
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Trial of Datopotamab Deruxtecan Versus Docetaxel in Advanced or Metastatic Non-Small Cell Lung Cancer with or without Genomic Alterations | Daiichi Sankyo Inc. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Datopotamab Deruxtecan | 1 | Unknown | 2021-04-30 | 2021-04-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.